91
Participants
Start Date
May 29, 2014
Primary Completion Date
August 7, 2015
Study Completion Date
February 10, 2017
Fruquintinib
After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
Placebo
Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
307 Hospital of PLA, Beijing
Beijing Cancer Hospital, Beijing
Beijing Chest Hospital, Beijing
The First Hospital of Jilin University, Changchun
The Cancer Hospital of Fudan University, Shanghai
Shanghai Chest Hospital, Shanghai
Nantong Tumor Hospital, Nantong
Linyi Tumor Hospital, Linyi
The First Affiliated Hosptial of College of Medicine, Zhejiang University, Hangzhou
Xi Nan Hospital, Third Military Medical University, Chongqing
Guangdong General Hospital, Guangzhou
West China Hospital, Chengdu
Shanghai Chest Hospital
OTHER
Hutchison Medipharma Limited
INDUSTRY